Controlled study for evaluation of the effect of AHCC(R) intake on eradication of high-risk type Human papillomavirus infection - HPV-AHCC Study

Watari Hidemichi0 sites180 target enrollmentMarch 19, 2019

Overview

No summary available.

Registry

who.int

Start Date

March 19, 2019

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

Female

Sponsor

Watari Hidemichi

•1\. Patients that have tested positive for high\-risk HPV through cytologic screening and HPV testing. (For the purposes of this study, high\-risk HPV is judged as types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68\.)
•2\. Patients that are between the ages of 20 and 54 upon date of registration for the study
•3\. Patients that, upon receiving a full explanation regarding study participation, fully understand what participation entails and have provided their informed consent in writing.

•1\. Patients that grade higher than CIN3 through tissue screening, or for whom treatment has been judged necessary.
•2\. Patients currently taking immunosuppressant medication such as steroids, or medication which suppresses TNF\-alpha production.
•3\. Patients who are regularly taking supplements which may influence immune function.
•4\. Patients with uncontrolled, progressive malignant tumors.
•5\. Patients with mental illness, or symptoms of mental illness, for whom study participation has been judged to be difficult.
•6\. Patients who are unable to return to the institution for follow\-up testing.
•7\. Patients who are pregnant, or who may possibly become pregnant.
•8\. Patients who are menopause.
•9\. Patients who, for reasons other than those stated above, have been deemed as incompatible with the study by the physician\-in\-charge.